Fundraising Fox
/Companies
Sign in

Syremis Therapeutics

Founded 2025 · 38 employees on LinkedIn · 6 known investors

Find your way into Syremis Therapeutics

Sign up to see every warm intro you have to Syremis Therapeutics

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Syremis Therapeutics team. We find them
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Syremis Therapeutics is a clinical-stage biopharmaceutical company developing neuropsychiatric medicines based on mechanisms including muscarinic M1/M4 agonism and NMDA antagonism. Its pipeline includes ST-905, a dual M1/M4 agonist in Phase 1 for schizophrenia, and ST-901, an NMDA antagonist in IND-enabling studies for major depressive disorder and bipolar depression.

BiotechHealthtechMental Health

Investors · 6

GV (Google Ventures)listed by GV (Google Ventures)Mountain View · $250K – $50M

How we know: GV (Google Ventures)'s portfolio page · funding news · calcalistech.com · open dataset · 5k.vc investor directory · Not right? Tell us

Bain Capital Life SciencesreportedBoston

How we know: funding news · calcalistech.com · Not right? Tell us

Also in the syndicate · 3

Dexcel PharmaleadPictetQVT

Funding

SEC filings, press & company announcements

$165M disclosed across 1 round · 2025

Source: company announcements and press reports — follow each round's link for the claim.

Related companies · 3

Eli LillyEli Lilly discovers, develops, manufactures, and markets human pharmaceutical products across cardiometabolic, oncology, immunology, and neuroscience therapeutic areas, selling to healthcare providers and patients in approximately 90 countries through wholesalers, direct sales representatives, and digital platforms.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Aclaris TherapeuticsAclaris develops investigational monoclonal antibodies and small-molecule inhibitors targeting immune pathways for the treatment of atopic, autoimmune, and respiratory diseases. The company's clinical and preclinical pipeline includes candidates in development for severe asthma, atopic dermatitis, and T-cell-mediated autoimmune conditions.

Companies working in the same space as Syremis Therapeutics.

Frequently asked questions

What does Syremis Therapeutics do?
Syremis Therapeutics is a clinical-stage biopharmaceutical company developing neuropsychiatric medicines based on mechanisms including muscarinic M1/M4 agonism and NMDA antagonism. Its pipeline includes ST-905, a dual M1/M4 agonist in Phase 1 for schizophrenia, and ST-901, an NMDA antagonist in IND-enabling studies for major depressive disorder and bipolar depression.
Who are Syremis Therapeutics's investors?
Syremis Therapeutics's investors include Third Rock Ventures, GV (Google Ventures), Bain Capital Life Sciences.
How much funding has Syremis Therapeutics raised?
Syremis Therapeutics has disclosed $165M raised across 1 round.